TY - JOUR
T1 - A case-control study of dietary salt intake in pediatric-onset multiple sclerosis
AU - McDonald, Jamie
AU - Graves, Jennifer
AU - Waldman, Amy
AU - Lotze, Timothy
AU - Schreiner, Teri
AU - Belman, Anita
AU - Greenberg, Benjamin
AU - Weinstock-Guttman, Bianca
AU - Aaen, Gregory
AU - Tillema, Jan Mendelt
AU - Hart, Janace
AU - Lulu, Sabeen
AU - Ness, Jayne
AU - Harris, Yolanda
AU - Rubin, Jennifer
AU - Candee, Meghan
AU - Krupp, Lauren B.
AU - Gorman, Mark
AU - Benson, Leslie
AU - Rodriguez, Moses
AU - Chitnis, Tanuja
AU - Mar, Soe
AU - Barcellos, Lisa F.
AU - Laraia, Barbara
AU - Rose, John
AU - Roalstad, Shelly
AU - Simmons, Timothy
AU - Casper, T. Charles
AU - Waubant, Emmanuelle
N1 - Funding Information:
Dr. Rose has research funding from Teva Neuroscience and Biogen. He is a member of the Medical Advisory Board for the DECIDE trial which is funded by Biogen and AbbVie.
Funding Information:
Dr. Krupp is supported by the National MS Society, NIH, Robert and Lisa Lourie Foundation, Department of Defense. She has received honoraria, consulting payments, grant support or royalties from Biogen, Medimmune, Novartis, Teva Neuroscience, Sanofi-Aventis, and EMD Serono.
Funding Information:
Dr. Chitnis has served as a consultant for Biogen-Idec, Teva Neurosciences, Novartis, Sanofi-Aventis, and has received grant support from NIH, National MS Society, Guthy-Jackson Charitable Foundation, CMSC and Merck-Serono and Novartis.
Funding Information:
Dr. Waubant is funded by the National MS Society, the NIH and the Race to Erase MS. She has received honorarium from Roche for an educational lecture. She volunteers on an advisory board for a clinical trial of Novartis.
Funding Information:
Dr. Waldman is supported by the NIH and previously received support from the National MS Society, American Brain Foundation, and The Calliope Joy Foundation. She received a one-time honorarium from Teva.
Funding Information:
This study was funded by IH-Grant R01NS071463-04 (PI: E. Waubant). Dr. Waubant is also funded by the Race to Erase MS. A grant from the National Multiple Sclerosis Society HC 0165 (PI: T.C. Casper) also supported this study. We acknowledge the commitment of MS patients and controls and family members to this study and thank them for the time they invested in providing answers to the environmental and food frequency questionnaires.Participating centers (with collaborators) are listed below in alphabetical order: Ann & Robert H. Lurie Children''s Hospital of Chicago (J. Rubin, L. Webb), Children''s Hospital of Alabama (J. Ness, Y. Harris), Boston Children''s Hospital (M. Gorman, L. Benson, S. Camposano), Children''s Hospital of Philadelphia (A. Waldman, G. Liu), Children''s Hospital Denver (T. Schreiner, K. Connelly), Children''s Hospital Salt Lake City (M. Candee, J. Narus), Loma Linda University Children''s Hospital (G. Aaen, M. Rundquist), Massachusetts General Hospital for Children (T. Chitnis, C. Crooks), Mayo Clinic (J. Tillema, J. M. Rodriguez, D. Weiss, J. Sorum), State University of New York at Stony Brook (L. Krupp, A. Belman, N. Oquendo), Texas Children''s Hospital (T. Lotze, M. Stocic), University of Buffalo (B. Weinstock-Guttman, M. Karpinski), University of California at San Francisco (E. Waubant, J. Graves, S. Lulu, J. Hart, M. Lee, J. McDonald), University of Texas Southwestern (B. Greenberg, P. Plumb), University of Utah Data Coordinating and Analysis Center (T. C. Casper, J. Rose, S. Roalstad, T. Hunt, C. Olsen, T. Simmons, W. Weber, B. Brown, E. Roan), Washington University School of Medicine in St. Louis (S. Mar, L. Grayson).
Funding Information:
Dr. Weinstock-Guttman received honoraria for serving in advisory boards and educational programs from Teva Pharmaceuticals, Biogen Idec, Novartis, Accorda, EMD Serono, Novartis, Genzyme and Sanofi. She also received support for research activities from the National Institutes of Health, National Multiple Sclerosis Society, National Science Foundation, Department of Defense, EMD Serono, Biogen Idec, Teva Neuroscience, Novartis, Accorda, Genzyme and the Jog for the Jake Foundation.
Funding Information:
Dr. Benson has research funding from Boston Children's Hospital Office of Faculty Development Career Development grant.
Funding Information:
This study was funded by NIH -Grant R01NS071463-04 (PI: E. Waubant). Dr. Waubant is also funded by the Race to Erase MS. A grant from the National Multiple Sclerosis Society HC 0165 (PI: T.C. Casper) also supported this study.
Publisher Copyright:
© 2016 Published by Elsevier B.V.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. Objective We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-control study. Methods Pediatric-onset CIS/MS cases within four years of onset and controls less than 22 years old recruited from 14 pediatric-MS centers were studied. Dietary sodium intake was assessed using the validated Block Kids Food Screener (NutritionQuest). Sodium intake, excess sodium, and sodium terciles were compared between cases and controls. Logistic regression models were adjusted for age, gender, ethnicity, body mass index, and socioeconomic status. Results Among 170 cases (mean age=15.2±3.5) and 331 controls (mean age=14.0±3.7), no significant difference in unadjusted mean sodium intake was found between cases (2044 mg/d) and controls (2030 mg/d, p=0.99). The proportion of subjects consuming excess sodium, based on the adequate intake for age and gender, was similar between cases and controls (65% versus 69%, p=0.34). There were no increased odds of higher sodium intake among cases as compared to controls (for each 100 mg/d increase in sodium, OR=1.00, 95% CI 0.98, 1.02; p=0.93, for excess sodium intake, OR=1.05, 95% CI 0.67, 1.64; p=0.84). Conclusions Our results show no strong association between dietary salt intake and pediatric-onset MS risk, suggesting that salt intake may not play a prominent role in susceptibility to MS in children.
AB - Background High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. Objective We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-control study. Methods Pediatric-onset CIS/MS cases within four years of onset and controls less than 22 years old recruited from 14 pediatric-MS centers were studied. Dietary sodium intake was assessed using the validated Block Kids Food Screener (NutritionQuest). Sodium intake, excess sodium, and sodium terciles were compared between cases and controls. Logistic regression models were adjusted for age, gender, ethnicity, body mass index, and socioeconomic status. Results Among 170 cases (mean age=15.2±3.5) and 331 controls (mean age=14.0±3.7), no significant difference in unadjusted mean sodium intake was found between cases (2044 mg/d) and controls (2030 mg/d, p=0.99). The proportion of subjects consuming excess sodium, based on the adequate intake for age and gender, was similar between cases and controls (65% versus 69%, p=0.34). There were no increased odds of higher sodium intake among cases as compared to controls (for each 100 mg/d increase in sodium, OR=1.00, 95% CI 0.98, 1.02; p=0.93, for excess sodium intake, OR=1.05, 95% CI 0.67, 1.64; p=0.84). Conclusions Our results show no strong association between dietary salt intake and pediatric-onset MS risk, suggesting that salt intake may not play a prominent role in susceptibility to MS in children.
KW - Dietary factors
KW - Epidemiology
KW - Multiple sclerosis
KW - Pediatric
KW - Salt
KW - Susceptibility
UR - http://www.scopus.com/inward/record.url?scp=84962560613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962560613&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2016.02.011
DO - 10.1016/j.msard.2016.02.011
M3 - Article
C2 - 27063630
AN - SCOPUS:84962560613
SN - 2211-0348
VL - 6
SP - 87
EP - 92
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
ER -